Apellis (APLS) is down -24.8%, or -$7.46 to $22.59.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
- Apellis falls -19.3%
- Buy Rating for Apellis Pharmaceuticals Driven by Strong Financial Performance and Promising Product Developments
- Positive Outlook for Apellis Pharmaceuticals: Strong Performance and Strategic Positioning Support Buy Rating
- Apellis reports Q3 EPS $1.71, consensus 94c